Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis

Tinea Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Tinea Pedis; Tinea Cruris; Tinea Corporis

Treatments: Drug: Product 33525

Study type: Interventional

Funder types: Industry

Identifiers

NCT01349998

MP-1005

Details and patient eligibility

About

The purpose of this study is to examine the long-term safety of treating recurrent episodes of tinea pedis for 14 days for each recurrence and recurrent episodes of tinea corporis or tinea cruris for 7 days for each recurrence with Product 33525.

Enrollment: 604 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Evidence of tinea cruris, tinea pedis, or tinea corporis. Additional criteria listed in protocol

Exclusion criteria

• Pregnancy and allergies. Additional criteria listed in protocol

Trial design

604 participants in 1 patient group

Safety Population

Experimental group

Treatment:

Drug: Product 33525